
Acumen Pharmaceuticals, Inc.
- Jurisdiction
United States - ISIN
US00509G2093 (ABOS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€122.81M - EBIT margin
0.0% - Net income
-€116.57M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 14, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |